nsclc: mechanisms of resistance to antiangiogenic therapy
Published 6 years ago • 142 plays • Length 3:00Download video MP4
Download video MP3
Similar videos
-
5:29
resistance to antiangiogenic therapy in lung cancer
-
5:29
mechanisms of anti-angiogenic therapy in lung cancer
-
6:11
how does antiangiogenic therapy work?
-
3:05
rationale behind antiangiogenic therapy in nsclc
-
5:46
resistance mechanisms in egfr nsclc
-
7:51
nsclc: egfr inhibition and resistance mechanisms
-
9:12
the current role for antiangiogenic therapy for nsclc
-
6:26
acquired mechanisms of resistance to pd-(l)1 blockade in nsclc
-
1:07
overcoming molecular mechanisms of resistance to therapies for non-small cell lung cancer
-
1:02
dr. socinski on mechanisms of resistance in lung cancer
-
1:33
dr. yang on resistance mechanisms from osimertinib in nsclc
-
6:32
antiangiogenic therapy for metastatic colorectal cancer
-
8:31
resistance mechanisms and sequencing for egfr nsclc
-
5:43
antiangiogenic therapy in advanced nsclc
-
4:32
resistance mechanisms in egfr-positive nsclc
-
3:47
antiangiogenic resistance in mrcc
-
1:23
mechanisms resulting in resistance to checkpoint inhibitors in nsclc
-
6:35
raffaele califano, esmo 2018 – mechanisms of resistance in non-small cell lung cancer
-
1:53
resistance to osimertinib in egfr-mutated nsclc